[U; Corrections; Added Details] Moderna and Merck Team Up Again -- This Time With mRNA-4157 / V940, An INT Candidate -- Now Enrolling A Phase III, In Australia, Against Certain Classes Of NSCLC...

As promised, this is the power alley item for the morning. This is also a very astounding time to be alive, in bioscience.

The idea here is individualized mRNA generated proteins, from one's own T-Cell factories. . . may be immensely helpful in stopping, and in fact reversing the spread of certain classes of lung cancers, using mRNA-4157, or (V940), in combination with pembrolizumab (Keytruda).

And the pair has a long history of working very well -- and very profitably -- together (think also of COVID-19- and Ebola- vaccines, here). Just search any of over 100 posts in the box, under the name "Moderna", above. Here's the latest:

. . .Moderna and Merck said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.

The therapy, V940, belongs to a class of treatments called m-RNA-based individualized neoantigen therapy (INT) and is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumor. . . .

The study is called INTerpath-002. It is a global, randomized, double-blind, placebo- and active-comparator-controlled Phase 3 trial evaluating approximately 868 patients with completely resected Stage II, IIIA or IIIB [N2] NSCLC. Following complete surgical resection and adjuvant chemotherapy, participants 18 years and older (in Australia, at first) will be dosed with the combo.

Now you know. Onward -- smiling at the world that is. . . now arriving. Excellent. And looking to the south this morning four times, already. . . Grin.

नमस्ते